Aligned Genetics, Inc.

KOSDAQ:A238120 Stock Report

Market Cap: ₩44.3b

Aligned Genetics Balance Sheet Health

Financial Health criteria checks 5/6

Aligned Genetics has a total shareholder equity of ₩33.0B and total debt of ₩2.4B, which brings its debt-to-equity ratio to 7.3%. Its total assets and total liabilities are ₩41.2B and ₩8.2B respectively. Aligned Genetics's EBIT is ₩2.6B making its interest coverage ratio -8. It has cash and short-term investments of ₩15.0B.

Key information

7.3%

Debt to equity ratio

₩2.40b

Debt

Interest coverage ratio-8x
Cash₩14.96b
Equity₩32.99b
Total liabilities₩8.21b
Total assets₩41.20b

Recent financial health updates

No updates

Recent updates

Aligned Genetics, Inc.'s (KOSDAQ:238120) Shareholders Might Be Looking For Exit

Nov 20
Aligned Genetics, Inc.'s (KOSDAQ:238120) Shareholders Might Be Looking For Exit

Aligned Genetics, Inc.'s (KOSDAQ:238120) Business Is Yet to Catch Up With Its Share Price

Aug 12
Aligned Genetics, Inc.'s (KOSDAQ:238120) Business Is Yet to Catch Up With Its Share Price

If You Like EPS Growth Then Check Out Aligned Genetics (KOSDAQ:238120) Before It's Too Late

Apr 06
If You Like EPS Growth Then Check Out Aligned Genetics (KOSDAQ:238120) Before It's Too Late

Update: Aligned Genetics (KOSDAQ:238120) Stock Gained 29% In The Last Three Years

Feb 11
Update: Aligned Genetics (KOSDAQ:238120) Stock Gained 29% In The Last Three Years

Financial Position Analysis

Short Term Liabilities: A238120's short term assets (₩21.8B) exceed its short term liabilities (₩1.2B).

Long Term Liabilities: A238120's short term assets (₩21.8B) exceed its long term liabilities (₩7.0B).


Debt to Equity History and Analysis

Debt Level: A238120 has more cash than its total debt.

Reducing Debt: A238120's debt to equity ratio has increased from 0% to 7.3% over the past 5 years.

Debt Coverage: A238120's debt is well covered by operating cash flow (110.5%).

Interest Coverage: A238120 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/04 10:50
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aligned Genetics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution